0001213900-24-005723.txt : 20240123
0001213900-24-005723.hdr.sgml : 20240123
20240123160522
ACCESSION NUMBER: 0001213900-24-005723
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240119
FILED AS OF DATE: 20240123
DATE AS OF CHANGE: 20240123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fabbio Patrick
CENTRAL INDEX KEY: 0001658859
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 24552514
MAIL ADDRESS:
STREET 1: 2 PITNEY COURT
CITY: BASKING RIDGE
STATE: NJ
ZIP: 07920
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 204580525
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-844-0337
MAIL ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: ArTara Therapeutics, Inc.
DATE OF NAME CHANGE: 20200110
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC
DATE OF NAME CHANGE: 20060420
4
1
marketforms-64339.xml
PRIMARY DOCUMENT
X0508
4
2024-01-19
0001359931
Protara Therapeutics, Inc.
TARA
0001658859
Fabbio Patrick
C/O PROTARA THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK
NY
10010
false
true
false
false
Chief Financial Officer
0
Common Stock
2024-01-19
4
A
false
22000
0.00
A
22000
D
Stock Option (Right to Buy)
1.91
2024-01-19
4
A
false
131000
0.00
A
2034-01-18
Common Stock
131000
131000
D
The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2024.
25% of the shares vest on the one year anniversary of January 19, 2024 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
/s/ Patrick Fabbio
2024-01-23